FDA approves Amgen's cheaper copy of arthritis drug Humira
WASHINGTON (Reuters) - The U.S. Food and Drug Administration on Friday approved a cheaper, biosimilar version of AbbVie's top-selling arthritis drug, Humira.
The drug, Amjevita, known also as adalimumab-atto, is made by biotechnology company Amgen Inc and was approved to treat rheumatoid arthritis, psoriatic arthritis, Crohn's disease, psoriasis and other conditions.
Amjevita is the fourth biosimilar to be approved by the FDA. Last month it approved Novartis AG's biosimilar version of Amgen's arthritis drug, Enbrel.
(Reporting by Toni Clarke; Editing by Sandra Maler)
© Copyright Reuters Ltd. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Reuters Ltd.
